Evidence map›Paper›PMID 34518829›Full record

ArticleEJHaem2021

Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy.

David García-Bernal, Edward Richardson, Israel Vlodavsky, Carmelo Carlo-Stella, Massimo Iacobelli, Rubén Jara, Paul G Richardson, Jose M Moraleda

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 4 countries.

David García-BernalDepartment of Medicine Hematopoietic Transplant and Cellular Therapy Unit IMIB-Arrixaca Virgen de la Arrixaca University Hospital University of Murcia Murcia Spain.ORCID https://orcid.org/0000-0001-6610-8442
Edward RichardsonFrank H. Netter M.D. School of Medicine Quinnipiac University North Haven Connecticut USA.
Israel VlodavskyTechnion Integrated Cancer Center Rappaport Faculty of Medicine Technion Haifa Israel.
Carmelo Carlo-StellaDepartment of Oncology and Hematology Humanitas Clinical and Research Center-IRCCS Rozzano-Milano Italy.
Massimo IacobelliTechitra s.r.l. Milan Italy.
Rubén JaraIntensive Care Unit, Virgen de la Arrixaca University Hospital University of Murcia Murcia Spain.
Paul G RichardsonDivision of Hematologic Malignancy Department of Medical Oncology Dana Farber Cancer Institute Harvard Medical School Boston Massachusetts USA.ORCID https://orcid.org/0000-0002-7426-8865
Jose M MoraledaDepartment of Medicine Hematopoietic Transplant and Cellular Therapy Unit IMIB-Arrixaca Virgen de la Arrixaca University Hospital University of Murcia Murcia Spain.ORCID https://orcid.org/0000-0001-9080-1466
Instituto Murciano de Investigación Biosanitaria · ESHarvard University · USHospital Universitario Virgen de la Arrixaca · ESHumanitas University · ITTechint (Italy) · ITTechnion – Israel Institute of Technology · ILYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34518829
PMCPMC8426874
OpenAlexW3176956378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.